PDF herunterladen
CC BY 4.0 · Pharmaceutical Fronts 2024; 06(04): e421-e429
DOI: 10.1055/s-0044-1796627
Original Article

Screening and Identification of Hypoxia-Inducible Factor Signaling Inhibitor with Antiangiogenic Activity

Chao Li   #
1   Department of Chemistry and Medi-X Pingshan, Southern University of Science and Technology, Shenzhen, People's Republic of China
,
Yuanzheng Wei   #
2   Guangdong Province Key Laboratory of Laboratory Animals, Guangdong Laboratory Animals Monitoring Institute, Guangzhou, Guangdong, People's Republic of China
,
Ping Wang   #
1   Department of Chemistry and Medi-X Pingshan, Southern University of Science and Technology, Shenzhen, People's Republic of China
,
Xiaoxian Xue
1   Department of Chemistry and Medi-X Pingshan, Southern University of Science and Technology, Shenzhen, People's Republic of China
,
Guangyao Wei
3   Advanced Medical Research Institute, Cheeloo College of Medicine, Shandong University, Jinan, People's Republic of China
,
Mu Chen
4   Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, People's Republic of China
,
Xinyun Zhang
5   ICE Bioscience Incorporated Company, Beijing, People's Republic of China
,
Lei Cai
2   Guangdong Province Key Laboratory of Laboratory Animals, Guangdong Laboratory Animals Monitoring Institute, Guangzhou, Guangdong, People's Republic of China
,
Yu Zhang
2   Guangdong Province Key Laboratory of Laboratory Animals, Guangdong Laboratory Animals Monitoring Institute, Guangzhou, Guangdong, People's Republic of China
,
Xumu Zhang
1   Department of Chemistry and Medi-X Pingshan, Southern University of Science and Technology, Shenzhen, People's Republic of China
,
Yingjun Li
1   Department of Chemistry and Medi-X Pingshan, Southern University of Science and Technology, Shenzhen, People's Republic of China
6   State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, People's Republic of China
› Institutsangaben Funding This work was supported by the National Natural Science Foundation of China (Grant No. 82204194) and the Guangdong Education Department (Grant No. 2022KTSCX107).
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Hypoxia-inducible factors (HIFs) play a key role in regulating cellular responses to low-oxygen conditions, particularly in promoting angiogenesis in tumor microenvironments. Aberrant HIF signaling enhances tumor growth and contributes to resistance against chemotherapy and radiotherapy. Targeting the HIF pathway has emerged as a promising strategy for cancer therapy. This study aimed to identify novel inhibitors of HIF signaling and evaluate their potential against the HIF–vascular endothelial growth factor (VEGF) axis for antiangiogenic therapy. In screening our in-house drug library using hypoxia response element dual-luciferase assay, HST3782, a novel 3-hydroxy-8-azabicyclo[3.2.1]octane-bridged compound, was identified as a promising HIF inhibitor, with IC50 of 1.028 μmol/L. In this work, the inhibitory effect of HST3782 on HIF signaling was confirmed in triple-negative breast cancer cells (SUM159) under hypoxic conditions (1% O2). Quantitative real-time polymerase chain reaction suggested the inhibitory effect of HST3782 on the expression of angiogenic genes, including VEGFa, VEGFR-1, BNIP3, and SERPINE1 in 786-O cells. Zebrafish model testing revealed that HST3782 inhibited intersegmental and subintestinal vessel development by up to 56% without marked toxicity. HST3782 was synthesized through a two-step 1,2,4 triazole cyclization reaction, followed by amide formation and ketone reduction steps. The last step of hydrogenation with sodium borohydride yielded a pair of endo-exo isomers. 2D-NOESY (Nuclear Overhauser effect spectroscopy) analysis confirmed that the compound's endo isomer (HST3782) had superior inhibitory effects relative to its exo form (8b). Given the above, HST3782 is a novel HIF inhibitor, with strong antiangiogenic effects and presents a valuable scaffold for future development of antiangiogenic drugs targeting the HIF–VEGF axis. Further studies are warranted to optimize HST3782's pharmacokinetics and therapeutic efficacy for antiangiogenic therapy in hypoxia-related malignancies.

Keywords

hypoxia-inducible factor - HIF pathway inhibitor - angiogenesis - zebrafish - bridged compound

# These authors contributed equally to this work.




Publikationsverlauf

Eingereicht: 04. April 2024

Angenommen: 05. November 2024

Artikel online veröffentlicht:
09. Dezember 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012; 148 (03) 399-408
    CrossrefPubMedSuche in Google Scholar
  • 2 Goldberg MA, Schneider TJ. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 1994; 269 (06) 4355-4359
    CrossrefPubMedSuche in Google Scholar
  • 3 Wu D, Potluri N, Lu J, Kim Y, Rastinejad F. Structural integration in hypoxia-inducible factors. Nature 2015; 524 (7565): 303-308
    CrossrefPubMedSuche in Google Scholar
  • 4 Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92 (12) 5510-5514
    CrossrefPubMedSuche in Google Scholar
  • 5 Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci U S A 1997; 94 (09) 4273-4278
    CrossrefPubMedSuche in Google Scholar
  • 6 Markolovic S, Wilkins SE, Schofield CJ. Protein hydroxylation catalyzed by 2-oxoglutarate-dependent oxygenases. J Biol Chem 2015; 290 (34) 20712-20722
    CrossrefPubMedSuche in Google Scholar
  • 7 Salceda S, Caro J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997; 272 (36) 22642-22647
    CrossrefPubMedSuche in Google Scholar
  • 8 Hogenesch JB, Chan WK, Jackiw VH. et al. Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J Biol Chem 1997; 272 (13) 8581-8593
    CrossrefPubMedSuche in Google Scholar
  • 9 Downes NL, Laham-Karam N, Kaikkonen MU, Ylä-Herttuala S. Differential but complementary HIF1α and HIF2α transcriptional regulation. Mol Ther 2018; 26 (07) 1735-1745
    CrossrefPubMedSuche in Google Scholar
  • 10 Genbacev O, Zhou Y, Ludlow JW, Fisher SJ. Regulation of human placental development by oxygen tension. Science 1997; 277 (5332) 1669-1672
    CrossrefPubMedSuche in Google Scholar
  • 11 Cho H, Du X, Rizzi JP. et al. On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models. Nature 2016; 539 (7627): 107-111
    CrossrefPubMedSuche in Google Scholar
  • 12 Deeks ED. Belzutifan: First Approval. Drugs 2021; 81 (16) 1921-1927
    CrossrefPubMedSuche in Google Scholar
  • 13 Beppu K, Nakamura K, Linehan WM, Rapisarda A, Thiele CJ. Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res 2005; 65 (11) 4775-4781
    CrossrefPubMedSuche in Google Scholar
  • 14 Falchook GS, Wheler JJ, Naing A. et al. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget 2014; 5 (21) 10280-10292
    CrossrefPubMedSuche in Google Scholar
  • 15 Befani CD, Vlachostergios PJ, Hatzidaki E. et al. Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J Mol Med (Berl) 2012; 90 (01) 45-54
    CrossrefPubMedSuche in Google Scholar
  • 16 Abd-Aziz N, Stanbridge EJ, Shafee N. Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation. Oncol Lett 2015; 10 (04) 2192-2196
    CrossrefPubMedSuche in Google Scholar
  • 17 Mangraviti A, Raghavan T, Volpin F. et al. HIF-1α- targeting acriflavine provides long term survival and radiological tumor response in brain cancer therapy. Sci Rep 2017; 7 (01) 14978
    CrossrefPubMedSuche in Google Scholar
  • 18 Naik R, Won M, Kim BK. et al. Synthesis and structure-activity relationship of (E)-phenoxyacrylic amide derivatives as hypoxia-inducible factor (HIF) 1α inhibitors. J Med Chem 2012; 55 (23) 10564-10571
    CrossrefPubMedSuche in Google Scholar
  • 19 Xu H, Wang J, Chen Y. et al. Design, synthesis and evaluation of the novel chalcone derivatives with 2,2-dimethylbenzopyran as HIF-1 inhibitors that possess anti-angiogenic potential. Eur J Med Chem 2023; 250: 115171
    CrossrefPubMedSuche in Google Scholar
  • 20 Xu XL, Yang YR, Mo XF, Wei JL, Zhang XJ, You QD. Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1α pathway. Eur J Med Chem 2017; 137: 45-62
    CrossrefPubMedSuche in Google Scholar
  • 21 Wehn PM, Rizzi JP, Dixon DD. et al. Design and activity of specific hypoxia-inducible factor-2α (hif-2α) inhibitors for the treatment of clear cell renal cell carcinoma: discovery of clinical candidate (S)-3-((2,2-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). J Med Chem 2018; 61 (21) 9691-9721
    CrossrefPubMedSuche in Google Scholar
  • 22 Liu Q, Guan C, Liu C, Li H, Wu J, Sun C. Targeting hypoxia-inducible factor-1alpha: A new strategy for triple-negative breast cancer therapy. Biomed Pharmacother 2022; 156: 113861
    CrossrefPubMedSuche in Google Scholar
  • 23 Li Y, Pasunooti KK, Peng H. et al. Design and synthesis of tetrazole- and pyridine-containing itraconazole analogs as potent angiogenesis inhibitors. ACS Med Chem Lett 2020; 11 (06) 1111-1117
    CrossrefPubMedSuche in Google Scholar
  • 24 Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438 (7070): 932-936
    CrossrefPubMedSuche in Google Scholar
  • 25 Carmeliet P, Dor Y, Herbert JM. et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394 (6692): 485-490
    CrossrefPubMedSuche in Google Scholar
  • 26 Choueiri TK, Kaelin Jr WG. Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat Med 2020; 26 (10) 1519-1530
    CrossrefPubMedSuche in Google Scholar
  • 27 Cheng H, Zhang L, Liu Y. et al. Design, synthesis and discovery of 5-hydroxyaurone derivatives as growth inhibitors against HUVEC and some cancer cell lines. Eur J Med Chem 2010; 45 (12) 5950-5957
    CrossrefPubMedSuche in Google Scholar